Menu
Cart 0

CBD News — schizophrenia

CBD and Schizophrenia

Posted by Susan Hatfield on

Some research has been conducted on the use of CBD to help treat schizophrenia. A study conducted in 2012 suggests that CBD was able to moderately prevent the endocannabinoid, anandamide, from degrading. When anandamide levels are elevated in cerebrospinal fluid, they correlate inversely to the psychotic symptoms of schizophrenia, meaning the symptoms are lessened or in some cases absent. 

Read more →

Get Involved: CBD Clinical Trials

Posted by Corey Hartley on

Research into the effects of cannabinoids, including cannabidiol, continues to progress into exploring an astonishing variety of systems and disorders. Although government restrictions on cannabis research hindered advancement until very recently, currently research has been blooming. If you would like to take part in this research and further our understanding of the biological mechanisms underlying the relief provided by the endocannabinoid system - check out the current clinical trials involving CBD. Many are currently recruiting participants all across the country - you could get involved!

Read more →

How Might Cannabidiol Impact Schizophrenia?

Posted by Seth B on

Cannabidiol (CBD) is a compound that has shown possible benefits in studies on a variety of animal models of mental health, including anxiety, bipolar disorder, and obsessive-compulsive disorder. Researchers have likewise also begun to examine CBD's potential utility with schizophrenia. Recently, we discussed a CBD clinical trial for schizophrenic individuals being conducted by a pharmaceutical firm, which could go a long way toward advancing our knowledge about CBD. In this post we will provide some more details on the science behind CBD and schizophrenia. Furthermore, recent medical studies on the endocannabinoid system (ECS) which has been shown as a potential therapeutic target...

Read more →

Using CBD to Treat Schizophrenia

Posted by Nate Hemmert on

CBD Shows Promise in Treating Schizophrenia GW Pharmaceuticals – a UK based biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform – recently announced that it has started Phase 2 clinical trials on a potential drug for the treatment of schizophrenia made from the marijuana compound cannabidiol (CBD). The company, which holds the only license for growing cannabis in the country and is publicly traded on NASDAQ, says the new drug features “purified CBD” as its active ingredient. To date, only one clinical trial has been conducted on CBD as an antipsychotic. The study,...

Read more →